Edwards Lifesciences Corporation · NYSE:EW

Edwards Lifesciences — Shareholder Meeting (March 2022)

10 slides from Edwards Lifesciences's shareholder meeting presentation, Mar 22, 2022

  1. Slide 1: Edwards Lifesciences Spring 2022 Stockholder Engagement

    Edwards Lifesciences Spring 2022 Stockholder Engagement

  2. Slide 2: Cautionary Statement and Use of Non-GAAP Financial Measures

    Cautionary Statement and Use of Non-GAAP Financial Measures This presentation may include forward-looking statements, including, but not limited to, financial forecasts, that involve risks and uncertainties that could cause actual results or experience to differ materially from historical results or

  3. Slide 3: We Request Your Support at the 2022 Annual Meeting of Stockholders

    We Request Your Support at the 2022 Annual Meeting of Stockholders Proposal 1. FOR Election of Eight Director Nominees Proposal 2. FOR Advisory Vote to Approve Named Executive Officer Compensation Proposal 3. FOR Ratification of Appointment of Independent Registered Public Accounting Firm Proposal 4

  4. Slide 4: Edwards Lifesciences at a Glance

    Patient-focused innovation Strategy Edwards Lifesciences at a Glance Sales overview(2) Company overview 95% 15,000+ Global Employees Sales from products with #1 global market share Market Capitalization(1) 1 Capital IQ, as of February 17, 2022; 2 2021 sales; 3 Transcatheter Mitral and Tricuspid Ther

  5. Slide 5: Execution of Patient-Focused Strategy Has Produced Exceptional Long-Term Results

    Execution of Patient-Focused Strategy Has Produced Exceptional Long-Term Results Focused on opportunities where patient demand is very large Track record of triple wins: Improved outcomes Enhanced quality of life Cost effectiveness Long-term investments have yielded high-value, organic growth Edward

  6. Slide 6: CEO Pay Elements and Performance Measures

    CEO Pay Element Components Corporate Performance Measures & Rationale Base Salary Cash Attract and retain qualified executives Annual Cash Incentive1 Corporate Financial Measurement Based on underlying revenue growth, adjusted net income, and adjusted free cash flow targets set at the beginning of t

  7. Slide 7: Highly Experienced & Independent Directors

    Men Women Highly Experienced & Independent Directors Michael A. Mussallem Joined in 2000 CEO and Chairman, Edwards Lifesciences Kieran T. Gallahue Joined in 2015 Former Chairman and CEO, CareFusion Corporation Leslie S. Heisz Audit Committee Chair Joined in 2016 Former Managing Director, Lazard Frèr

  8. Slide 8: Commitment to Stockholder Engagement and Responsiveness

    Commitment to Stockholder Engagement and Responsiveness We have consistently contacted stockholders holding >50% of outstanding stock each year since 2015 to discuss topics of interest with active participation from our Lead Independent Director 2022 2019 2015 Discussion TOPICS Governance features a

  9. Slide 9: Board Recommends Vote Against the Proposal to Reduce the Special Meeting Rights Ownership Threshold

    Board Recommends Vote Against the Proposal to Reduce the Special Meeting Rights Ownership Threshold Current 15% Threshold is appropriate given Ownership Base Strong Corporate Governance and Record of Accountability Robust stockholder engagement during which stockholders have not raised special meeti

  10. Slide 10: Edwards

    Edwards

Edwards Lifesciences — Shareholder Meeting (March 2022) on 6ix